Prognosis and outcome of patients with pancreatic metastases from renal cell carcinoma: When the site matters.

484 Background: Pancreatic metastases from renal cell carcinoma (PmRCC) are uncommon and their prognostic value in the era of targeted terapies (TTs) is not well defined. We evaluated the outcome of a cohort of PmRCC patients (pts) who were treated with either surgery and TTs. Methods: PmRCC pts treated between 1993 and 2014 were identified from the databases of 10 European centers. Clinical records were retrospectively reviewed and pts characteristics, including demographics and clinical outcome, were analyzed. Kaplan-Meier methods and log-rank test were used to evaluate progression-free survival (PFS) and overall survival (OS). Cox’s proportional hazard models were used for OS analysis. Results: A total of 232pts were evaluated. Median age was 61 years, sex ratio M/F was 147/85, and PmRCC were synchronous in 69 pts (30%). Pts treated with pancreatic surgery (including radiosurgery) were 67 (29%), while patients receiving systemic treatment were 210 (91%). Pts with only PmRCC were 23 (11%), whereas in th...